UCB Gets US FDA Approval for Psoriasis Drug
By Helena Smolak
UCB received approval from the U.S. Food and Drug Administration for a drug to treat severe plaque psoriasis for which the company expects global peak annual sales of at least 4 billion euros ($4.23 billion).
The Belgian biopharmaceutical firm said Wednesday that its bimekizumab drug, which will be commercialized as Bimzelx, was approved by the FDA as a treatment for the skin disease psoriasis in adults.
"With bimekizumab now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S.", it said.
The FDA approval was backed by data from three Phase 3 studies, the company said.
UCB on Tuesday said the FDA approved its Zilbrysq for the treatment of adults with myasthenia, an autoimmune disorder.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
October 18, 2023 11:21 ET (15:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks